TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Aura Biosciences Stock

Aura Biosciences Stock

aurabiosciences.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $225.08MM

Aura Biosciences is a biotechnology company developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed.

Learn more about Aura Biosciences IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Aura Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Aura Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Aura Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Elisabet de los Pinos Ph.D
Co-Founder, Chief Executive Officer & Board Member
Denis O'Shaughnessy Ph.D
Head of Clinical Development
Richard Peters Ph.D
Advisor
Andrew Russell Ph.D
Director, Manufacturing
Stephen Monks Ph.D
Senior Vice President, Development
Alan Walts Ph.D
Executive Chairman
Julie Feder
Chief Financial Officer
Cadmus Rich MD
Chief Medical Officer
Michele Keough
Senior Vice President, R&D Operations

Board Members

Dale Pfost Ph.D
Advent Venture Partners
Elisabet de los Pinos Ph.D
Casper Breum
Lundbeckfonden
Henri Termeer
Javier García
Columbus Venture Partners
Rajesh Parekh Ph.D
Advent Life Sciences
Arthur Pappas
Chiesi Ventures
Giovanni Mariggi Ph.D
Medicxi
Joël Jean-Mairet Ph.D
Ysios Capital
Salvador Garcia-Atance Ph.D
Israel Ruiz
Alan Walts Ph.D
Mark Chin
Arix Bioscience

Other companies like Aura Biosciences in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

Business Wire 01/07/2020
Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors
Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tum

Trending Companies

Frequently Asked Questions

Updated on: Apr 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.